rethinkTHC Search
Menu
Study breakdown

The Rise of Semi-Synthetic Cannabinoids in Europe

Narrative ReviewPreliminary evidence
The takeaway

Over 30 semi-synthetic cannabinoids derived from hemp CBD are now circulating in Europe, marketed as legal THC alternatives with largely unknown safety profiles.

Anyone curious about HHC and similar hemp-derived products, forensic scientists, drug policy researchers, public health professionals monitoring novel psychoactive substances.

What the researchers found

Since hexahydrocannabinol (HHC) first appeared in Europe in late 2022, the semi-synthetic cannabinoid market has expanded rapidly. The European Union Drugs Agency now monitors over 30 of these compounds, which are manufactured by chemically modifying CBD extracted from legal hemp.

These products are marketed as legal replacements for THC and sold in consumer-friendly forms including vapes, edibles, and herbal products. The chemical modifications target THC's molecular structure to increase potency, change how the body processes them, or circumvent existing drug laws.

The review identified serious concerns: products are frequently mislabeled, may contain undeclared substances or contaminants, and analytical detection is difficult because many semi-synthetic cannabinoids closely resemble natural cannabis compounds. Almost nothing is known about their pharmacological and toxicological profiles, metabolic pathways, or long-term health effects.

Why it matters

Semi-synthetic cannabinoids represent a new category of psychoactive substances that exploits the legal hemp supply chain. Because they're derived from legal CBD rather than manufactured entirely from scratch like older synthetic cannabinoids (Spice/K2), they occupy a regulatory gray zone in many jurisdictions. Their rapid proliferation with minimal safety data creates a public health challenge that existing drug testing and regulation wasn't designed to handle.

The numbers in context

Over 30 semi-synthetic cannabinoids monitored by the European Union Drugs Agency. HHC first detected in Europe in late 2022. Products found in vapes, edibles, and herbal forms. 17 EU member states plus the UK have implemented some form of regulatory response.

How the study worked

Narrative review synthesizing available data on semi-synthetic cannabinoids from the European Union Drugs Agency monitoring system, published literature, and forensic science reports. Examined chemical characteristics, market dynamics, regulatory responses, and analytical detection challenges.

Who was studied

Overview of semi-synthetic cannabinoids in the European market.

What this study cannot tell us

As a narrative review, this does not systematically assess all available evidence. Most data come from European monitoring systems and may not reflect the situation in other regions. The rapidly evolving nature of the market means specific compound counts and regulatory responses may be outdated quickly.

How to read the evidence

Narrative review of an emerging phenomenon — provides important surveillance data but lacks the controlled studies needed to quantify health risks of specific compounds.

When this study was published

Published in 2026, capturing the state of the rapidly evolving semi-synthetic cannabinoid market through late 2025.

The bigger picture

The semi-synthetic cannabinoid phenomenon illustrates how legal hemp markets can become feedstocks for novel psychoactive substances. Each time regulators ban one compound, manufacturers make minor structural tweaks to create a new unregulated analog — a cat-and-mouse dynamic familiar from the synthetic cannabinoid era but now occurring within the legal cannabis supply chain itself. This has implications for consumer safety, drug testing, and the broader debate about how cannabis regulation interacts with novel drug markets.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

  • How do the health risks of semi-synthetic cannabinoids compare to natural THC? Can existing drug testing methods reliably distinguish semi-synthetic cannabinoids from natural cannabis use? Will regulation of the hemp-derived CBD supply chain be necessary to control this market?

Read the original research

Semi-synthetic cannabinoids: Recent developments, analytical challenges and strategic responses.

Forensic science international, 381, 112823

Forensic Science International is a reputable journal focusing on forensic science and toxicology.

Citation

Christie, Rachel; Conlon, Ross; Néfau, Thomas; Gallegos, Ana. (2026). Semi-synthetic cannabinoids: Recent developments, analytical challenges and strategic responses.. Forensic science international, 381, 112823. https://doi.org/10.1016/j.forsciint.2026.112823

Explore the wider topic